C. Michael Gibson/LinkedIn
Nov 8, 2025, 11:18
C. Michael Gibson and Atul Verma on OCEAN Trial: Rivaroxaban VS Aspirin in AF
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Atul Verma and I discuss the OCEAN trial: In AF patients after successful catheter ablation, is long-term anticoagulation with low-dose rivaroxaban more effective than aspirin in preventing stroke or systemic embolism?
AHA25 View it here.”
Stay updated with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration